Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis
Metadatos
Mostrar el registro completo del ítemAutor
Tristán, Ana Isabel; Caba Pérez, Octavio; Jiménez Luna, Cristina; Melguizo Alonso, Consolación; Prados Salazar, José CarlosEditorial
Wiley
Fecha
2023Referencia bibliográfica
Tristán AI, González-Flores E, Salmer on AM, et al. Serum nuclear magnetic resonance metabolomics analysis of human metastatic colorectal cancer: Biomarkers and pathway analysis. NMR in Biomedicine. 2023;e4935. [doi:10.1002/nbm.4935]
Patrocinador
Junta de Andalucia 102C2000004, UAL2020-AGR-B1781, P20_01041; Gobierno de España MCIN/AEI/10.13039/501100011033/Unión Europea “Next GenerationEU”/PRTR (PDC2021–121248-I00 and PLEC2021–007774); Instituto de Salud Carlos III (ISCIII) (PI19/01478) (FEDER); CTS-107; FQM-376Resumen
We describe the use of nuclear magnetic resonance metabolomics to analyze blood
serum samples from healthy individuals (n = 26) and those with metastatic colorectal
cancer (CRC; n = 57). The assessment, employing both linear and nonlinear multivari-
ate data analysis techniques, revealed specific metabolite changes associated with
metastatic CRC, including increased levels of lactate, glutamate, and pyruvate, and
decreased levels of certain amino acids and total fatty acids. Biomarker ratios such as
glutamate-to-glutamine and pyruvate-to-alanine were also found to be related to
CRC. The study also found that glutamate was linked to progression-free survival and
that both glutamate and 3-hydroxybutyrate were risk factors for metastatic CRC.
Additionally, gas chromatography coupled to flame-ionization detection was utilized
to analyze the fatty acid profile and pathway analysis was performed on the profiled
metabolites to understand the metabolic processes involved in CRC. A correlation
was also found between the presence of certain metabolites in the blood of CRC
patients and certain clinical features.